Compare Charles River Laboratories Intl. Inc (CRL) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Roundhill Magnificent Seven ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.69 (market cap $14.23B), while Roundhill Magnificent Seven ETF trades at $73.8 (market cap $5.78B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.5× Roundhill Magnificent Seven ETF's market cap, and Roundhill Magnificent Seven ETF is more actively traded (4,410,665 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| CRL | MAGS | |
|---|---|---|
Market Cap | $14.23B | $5.78B |
Volume | 1,176,885 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $310.77 | $73.90 |
52-Week Low | $149.93 | $55.39 |
Typical Hold Time | 33 Days | 36 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.63, down slightly by 0.08% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains. Recent news highlights ongoing investor debate about the Magnificent Seven's leadership role amid shifting AI investment trends.
The ETF faces near-term pressure from underperformance versus the S&P 500 but maintains long-term growth potential through diversified tech exposure. Key risks include concentration in seven stocks and market rotation away from mega-caps, while the bullish technical setup suggests potential for near-term recovery if AI momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
